Trial Profile
An Open-Label, Multicentre, Long-Term Follow-Up Study to Investigate the Safety and Durability of Response Following Dosing of a Novel Adeno-Associated Viral Vector (FLT180a) in Patients With Haemophilia B
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Verbrinacogene setparvovec (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Freeline Therapeutics
- 18 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 12 Jul 2022 Results (data cutoff date: 20 Sep 2021) reporting safety and efficacy data at median follow-up of 27.2 months from clinical trial NCT03369444 and its long term follow-up study NCT03641703 published in the New England Journal of Medicine
- 30 Nov 2020 Status changed from recruiting to active, no longer recruiting.